My peer-based valuation of Bisantrene.
This valutation is reinforced by a comparison done to the 2020 buyout of Immunomedics by Gilead for USD $21B. I recognise the limitations of comparing a company that has achieved a recent FDA approval with RAC, a company that is in the preclinical stages of understanding the potential for Bisantrene as an FTO inhibitor. However, I believe that because RAC and Bisantrene have the avantage of historic FDA approval in France and a massive set of phase I, II, and III historical data, it positions them at enough of a distance from preclinical stage to make the comparison more logical and realistic. Within the PDF you will discover that Trodelvy is a suitable molecule to compare to based on the target protein expression in multiple cancer types, potential drug synergies, breast cancer market, and singular FDA approval.
Highlights of the PDF include:
- FTO has been established as a significant prognostic marker in more cancer types than Trop-2 (22 to 13)
- Bisantrene has potentially more opportunity for cancer therapy synergy than Trodelvy through the FTO mechanism (6 to 5)
- Bisantrene has the potential to address at least 60% of the breast cancer market, which is three to four times more than Trodelvy currently (15-20%).
- Both drugs have received one FDA approval
- Clear demonstration of value and potential of a potent FTO inhibitor, like Bisantrene, when compared to Trodelvy
I estimate the value of bisantrene at above $100 per share, provided RAC can realise the true clinical potential of bisantrene as an anti-cancer agent as well as an FTO inhibitor.
This information has been gathered to my best knowledge and undertanding, which may be incorrect and/or inconsistent.
All IMO - DYOR
(20min delay)